Persistence of the prothrombotic state after acute coronary syndromes: Implications for treatment

American heart journal

Volumn 143, Issue 2, 2002, Pages 205-216

  Bahit, Maria Cecilia ^a   Granger, Christopher B ^a   Wallentin, Lars ^b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; LOW MOLECULAR WEIGHT HEPARIN; TICLOPIDINE; WARFARIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DRUG ANTAGONISM; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TIME; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ASPIRIN; CORONARY THROMBOSIS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MYOCARDIAL INFARCTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; THROMBOLYTIC THERAPY; TICLOPIDINE; TIME FACTORS; WARFARIN;

EID: 0036483898     PISSN: None     EISSN: 10976744     Source Type: Journal    
DOI: 10.1067/mhj.2002.120767     Document Type: Article

References (65)

1. V Fuster Z Fayad J. Badimon Acute coronary syndromes: biology Lancet 353 II Suppl 1999 5 9
2. P Theroux V. Fuster Acute coronary syndromes: unstable angina and non-Q wave myocardial infarction Circulation 97 1998 1195 1206
3. M. Davies Stability and instability: two faces of coronary atherosclerosis: the Paul Dudley White Lecture 1995 Circulation 94 1996 2013 2020
4. E Braunwald EM Antman JW Beasly ACC/AHA guidelines for the management of patients with unstable angina and non-ST elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with unstable angina) J Am Coll Cardiol 36 2000 970 1062
5. E Van Belle JM Lablanche C Bauters Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction: natural history and the effect of thrombolysis Circulation 97 1998 26 33
6. PA Merlini KA Bauer L Oltrona Persistent activation of coagulation mechanism in unstable angina and myocardial infarction Circulation 90 1994 61 68
7. PA Merlini D Ardissino RD Rosenberg In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectoris Arterioscler Thromb Vasc Biol 20 2000 2162 2166
8. KA Ault CP Cannon J Mithchell Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial J Am Coll Cardiol 33 1999 634 639
9. EJ Topol J. Yaday Recognition of the importance of embolization in atherosclerotic vascular disease Circulation 101 2000 570 580
10. EM Ohman PW Armstrong R Christenson Cardiac troponin levels for risk stratification in acute myocardial ischemia N Engl J Med 335 1996 1333 1341
11. C Heeschen C Hamm B Goldman Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban Lancet 354 1999 1757 1762
12. C Hamm C Heeschen B Goldman Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin levels N Engl J Med 340 1999 1623 1629
13. FRISC Investigators Long-term molecular mass heparin in unstable coronary artery disease: FRISC II prospective randomized multicentre study Lancet 354 1999 701 707
14. A Oler MA Whooley J Oler Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta analysis JAMA 276 1996 811 815
15. P Theroux D Waters J Lam Reactivation of unstable angina after discontinuation of heparin N Engl J Med 327 1992 141 145
16. CB Granger J Hirsh RM Califf Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial Circulation 93 1996 870 878
17. CB Granger R Becker R Tracy Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I trial J Am Coll Cardiol 31 1998 497 505
18. MC Bahit EJ Topol RM Califf Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb J Am Coll Cardiol 37 2001 1001 1007
19. TRIM Study Group A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients: a double-blind, randomised, dose-finding study Eur Heart J 18 1997 1416 1425
20. R Linder J Olgren N Egberg The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease Eur Heart J 20 1999 506 518
21. G Mombelli O Marchetti A Haeberli Effect of intravenous heparin infusion on thrombin-antithrombin complex and fibrinopeptide A in unstable angina Am Heart J 136 1998 1106 1113
22. P Merlini D Ardissino KA Bauer Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes Arterioscler Thromb Vasc Biol 17 1997 1325 1330
23. RC Becker FA Spencer Y Li Thrombin generation after abrupt cessation of intervenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombic potential J Am Coll Cardiol 34 1999 1020 1027
24. CB Granger JM Miller EG Bovill Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes Circulation 91 1995 1929 1935
25. M Ernofsson F Strekerud H Toss Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease Thromb Hemost 79 1998 491 494
26. AB Greenbaum RA Harrington MP Hudson Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes: PURSUIT Investigators J Am Coll Cardiol 37 2001 492 498
27. ISIS-2 Second International Study of Infarct Survival Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2 Lancet 2 1988 349 360
28. P Theroux H Ouimet J McCans Aspirin, heparin, or both to treat acute unstable angina N Engl J Med 319 1988 1105 1111
29. HD Lewis JW Davis DG Archibald Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration cooperative study N Engl J Med 309 1983 396 403
30. JA Cairns M Gent J Singer Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial N Engl J Med 313 1985 1369 1375
31. RISC Group Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease Lancet 336 1990 827 830
32. Antiplatelet Trialists' Collaboration Collaborative overview of randomized trials of antiplatelet therapy: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ 308 1994 81 106
33. B Lindahl H Toss A Siegbahm Markers of myocardial damage and inflammation in relation to long term mortality in unstable coronary artery disease: FRISC Study Group. Fragmin during Instability in Coronary Artery Disease N Engl J Med 343 2000 1139 1147
34. E. Gurfinkel Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia J Am Coll Cardiol 26 1995 313 318
35. M Cohen C Demers E Gurfinkel A comparison of low molecular heparin with unfractionated heparin for unstable coronary artery disease N Engl J Med 337 1997 447 452
36. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAXIS (Fraxiparine in Ischaemic Syndrome) Eur Heart J 20 1999 1553 1562
37. W Klein A Buchwald S Hillis Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease Circulation 96 1997 61 68
38. Fragmin during Instability in Coronary Artery Disease FRISC Study Group Low-molecular-weight heparin during instability in coronary artery disease Lancet 347 1996 561 568
39. E Antman C McCabe E Gurfinkel Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial Circulation 100 1999 1593 1601
40. E Antman M Cohen D Radley Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis Circulation 100 1999 1602 1608
41. Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomized multicenter study: Fragmin and Fast Revascularisation During Instability in Coronary Artery Disease Investigators Lancet 354 1999 708 715
42. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis ASPECT Research Group Effect of long term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction Lancet 343 1994 499 503
43. P Smith H Arnesen I. Holme The effect of warfarin on mortality and reinfarction after myocardial infarction N Engl J Med 323 1990 147 152
44. S Anand S Yusuf J Pogue Long term oral anticoagulant therapy in patients with unstable angina or suspected non Q wave myocardial Infarction: OASIS pilot study results Circulation 98 1998 1064 1070
45. S Anand S. Yusuf The OASIS investigators: randomised trial of oral anticoagulant therapy in patients with acute ischemic syndromes without ST elevation: importance of good compliance J Am Coll Cardiol 33 1999 396A
46. Coumadin Aspirin Reinfarction Study CARS Investigators Randomized double-blind trial of fixed low dose warfarin with aspirin after myocardial infarction Lancet 350 1997 389 396
47. L. Fiore Combination Hemotherapy and Mortality Prevention CHAMP study Plenary Session XII: Late Breaking Clinical Trials. Proceedings of the 72nd Scientific Sessions of the American Heart Association; 1999 Nov 7-10; Atlanta, Ga 1999 The Association Atlanta
48. RF. Van Es The Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Proceedings of the 22nd Congress of the European Society of Cardiology; 2000 Aug 26-30; Amsterdam, The Netherlands 2000 The Society Amsterdam
49. MA. Brower The Antithrombotics in the Prevention of Reocclusion in Coronary Thrombosis-2 (APRICOT-2) Proceedings of the 22nd Congress of the European Society of Cardiology; 2000 Aug 26-30; Amsterdam, The Netherlands 2000 The Society Amsterdam
50. H. Arnesen Warfarin-Asprin Re-Infarction Study WARIS II. Plenary Session: Hotline Proceedings of the 23rd Congress of the European Society of Cardiology; 2001 Sept 2-5; Stockholm, Sweden 2001 The Society Stockholm
51. CAPRIE Investigators A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 348 1996 1329 1339
52. CURE Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
53. SR Mehta S Yusuf RJG Peters Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
54. DP Chew DL Bhatt S Sapp Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials Circulation 103 2001 201 206
55. WW O'Neill P Serruys M Knudtson Long-term treatment with a platelet glycoprotein receptor antagonist after percutaneous coronary revascularization N Engl J Med 342 2000 1316 1324
56. CP Cannon CH McCabe RG Wilcox Oral glycoprotein IIb/IIIa inhibition with orbofiban with unstable coronary syndromes (OPUS TIMI 16) trial Circulation 102 2000 149 156
57. SYMPHONY Investigators Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial Lancet 355 2000 337 345
58. Second SYMPHONY Investigators Randomized trial of aspirin, sibrafiban or both for secondary prevention after acute coronary syndromes Circulation 103 2001 1727 1733
59. EJ Topol D Easton P Amarenco Design of the Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial Am Heart J 139 2000 927 933
60. M Casey C Fornari G Bozovich Increased expression of platelet P-selectin in patients treated with oral orbofiban in the OPUS TIMI 16 trial [abstract] Proceedings of the 72nd Scientific Sessions of the American Heart Association; 1999 Nov 7-10; Atlanta, Ga 1999 The Association Atlanta
61. SR Adderley DJ. Fitzgerald Glycoprotein IIb/IIIa antagonist induce apoptosis in rat cardiomyocytes by Caspase-3 activation J Biol Chem 275 2000 5760 5766
62. RM Califf LH Woodlief FE Harrell Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators Am Heart J 133 1997 630 639
63. B Lindahl P Venge L Wallentin Troponin T identifies patients with unstable coronary artery disease who benefit from long term antithrombotic protection J Am Coll Cardiol 29 1997 43 48
64. LK Newby EM Ohman RH Christenson Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: the PARAGON-B troponin T substudy Circulation 103 2001 2891 2896
65. ML Simoons for the GUSTO IV investigators Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial Lancet 357 2001 1915 1924